Trial Profile
A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active Controlled Clinical Trial to Determine the Non-inferior Efficacy and Safety of CinnoRA® (Adalimumab, CinnaGen Co.) Versus Humira® for Treatment of Active RA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Folic acid; Methotrexate; Prednisolone
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors CinnaGen
- 29 May 2017 Status changed from active, no longer recruiting to completed.
- 22 Sep 2016 New trial record